The estimated Net Worth of Charlene A. Banard is at least 111 千$ dollars as of 16 May 2023. Charlene Banard owns over 19,040 units of Applied Molecular Transport stock worth over 71,763$ and over the last 3 years Charlene sold AMTI stock worth over 38,842$.
Charlene has made over 1 trades of the Applied Molecular Transport stock since 2023, according to the Form 4 filled with the SEC. Most recently Charlene sold 19,040 units of AMTI stock worth 38,842$ on 16 May 2023.
The largest trade Charlene's ever made was selling 19,040 units of Applied Molecular Transport stock on 16 May 2023 worth over 38,842$. On average, Charlene trades about 3,173 units every 0 days since 2022. As of 16 May 2023 Charlene still owns at least 276,010 units of Applied Molecular Transport stock.
You can see the complete history of Charlene Banard stock trades at the bottom of the page.
Charlene's mailing address filed with the SEC is AMTI, C/O CORPORATION TRUST COMPANY, TRUST CENTER, 1209 ORANGE ST., WILMINGTON, DE, 19801.
Over the last 4 years, insiders at Applied Molecular Transport have traded over 9,673,149$ worth of Applied Molecular Transport stock and bought 3,091,278 units worth 40,384,206$ . The most active insiders traders include Capital Group, Llcepq Llc A...、Helen Susan Kim、Tahir Ph.D. Mahmood. On average, Applied Molecular Transport executives and independent directors trade stock every 24 days with the average trade being worth of 26,155$. The most recent stock trade was executed by Tahir Ph.D. Mahmood on 22 November 2023, trading 286,320 units of AMTI stock currently worth 45,811$.
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It is also involved in developing AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase Ia clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Applied Molecular Transport executives and other stock owners filed with the SEC include: